Customers have complained that a telehealth network selling compounded GLP-1s has been ripping them off—even after it had to pay $5 million to clients as part of a settlement with the US government.
For years, people from CEOs to novelists have taken tiny amounts of psychedelics to support well-being. New research shows that benefits for depression may be attributable to a placebo effect.
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still haven’t finished.
Research into whether drugs like ayahuasca can mitigate the effects of traumatic brain injury is in its infancy. Pro athletes like Jordan Poyer are forging ahead anyway.
